Context Therapeutics Inc. (6K9)
XSTU 
Summary
6K9 Chart
Context Therapeutics: Undervalued Cancer Fighter
Context Therapeutics offers a compelling long opportunity, with three differentiated bispecific T-cell engagers targeting solid tumors and strong early-stage clinical momentum. The company is well-capitalized, with $89 million in cash and access to additional funding, supporting operations through key Phase I data milestones into 2027. CNTX trades at a deep discount to book value and is technically oversold; positive clinical data could trigger a significant re-rating and share price upside.
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Context Therapeutics Inc. (CNTX), Blue Bird (BLBD), Dycom Industries (DY) and Leidos (LDOS).
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Context Therapeutics Inc. (6K9) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Context Therapeutics Inc. ever had a stock split?
Context Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Martin A. Lehr CEO | XSTU Exchange | US21077P1084 ISIN |
| US Country | 15 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Context Therapeutics Inc. is a biopharmaceutical company engaged in the development of therapeutic products designed to treat solid tumors, a major area of need in oncology. The company's approach involves targeting malignant cells with precision, aiming to improve the outcomes for patients battling various forms of cancer. Established in 2015, Context Therapeutics has positioned itself within the competitive landscape of cancer therapy developers by focusing on innovative biotechnologies. It is located in Philadelphia, Pennsylvania, where it conducts its primary research and development activities. Through strategic collaborations, such as with Integral Molecular, Inc., Context Therapeutics Inc. seeks to advance its mission of bringing novel cancer therapies from the lab to the clinic.
Products and Services
Context Therapeutics Inc. is actively developing a portfolio of products and services designed to address the complexities of cancer treatment, with a particular focus on solid tumors. Key developments include:
- CTIM-76: This is the lead program candidate of Context Therapeutics Inc., representing a significant advancement in the field of cancer immunotherapy. CTIM-76 is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody, designed to redirect T-cell-mediated lysis towards malignant cells expressing CLDN6. This innovative mechanism of action aims to harness the body's immune system to more effectively target and eliminate cancer cells, offering a promising avenue for therapy in tumors where CLDN6 is prevalent.
- Collaboration and Licensing Agreement with Integral Molecular, Inc.: To further its goal of developing effective cancer therapies, Context Therapeutics Inc. has entered into a strategic partnership with Integral Molecular, Inc. This collaboration focuses on the development of a CLDN6 bispecific monoclonal antibody intended for cancer treatment. It reflects the company's commitment to leveraging external expertise and resources to accelerate the development of its proprietary cancer therapies, enhancing its ability to address unmet needs in oncology.
